Back

Ancestry-specific rewiring of BCR-MAPK signaling in sarcoidosis B cells

Dunn, C. M.; Watkins, C.; Hallum, G.; Pezant, N.; Rasmussen, A.; Gaffney, P. M.; Bagavant, H.; Deshmukh, U. S.; Montgomery, C.

2026-04-22 immunology
10.64898/2026.04.20.718985 bioRxiv
Show abstract

Sarcoidosis is a heterogenous disease of unknown etiology characterized by non-caseating granulomas. Disease prevalence and presentation vary significantly by ancestry and ranges from acute, self-resolving disease to severe, chronic disease. Following previous reports suggesting B cells in the development and pathogenesis of sarcoidosis, we present here results of single-cell RNA sequencing, supporting B cell involvement in sarcoidosis through altered immediate early response, rewiring of MAPK signaling, and ancestry-specific preferential expansion of B cell receptors. Peripheral blood mononuclear cells were obtained from individuals of African or European Ancestry (AA and EA, respectively) including 48 healthy controls, 59 sarcoidosis patients, and 28 systemic lupus erythematosus (SLE) patients. SLE samples were used as a disease control. Differential expression analysis highlighted many differentially expressed genes (DEGs) with almost 5x more in the AA sarcoidosis versus AA control group compared to the EA sarcoidosis versus EA control group. B cells had the most DEGs of all cell types and expression patterns were similar between ancestries, however, sarcoidosis had an opposite transcription pattern than SLE, demonstrating an alternative immune response to acute activation than that seen in a prototypical autoinflammatory disease. This trend was maintained when examining specialized B cell subsets, with the most pronounced effect in the AA sarcoidosis versus AA control comparison. Our results strongly support further investigation of the role of humoral immune response in sarcoidosis and the potential to highlight patient groups likely to benefit from existing B cell therapies.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
586 papers in training set
Top 0.1%
22.6%
2
Clinical Immunology
21 papers in training set
Top 0.1%
9.2%
3
Arthritis & Rheumatology
33 papers in training set
Top 0.1%
6.8%
4
Immunology
29 papers in training set
Top 0.1%
6.3%
5
JCI Insight
241 papers in training set
Top 1%
4.0%
6
Scientific Reports
3102 papers in training set
Top 36%
3.6%
50% of probability mass above
7
Rheumatology
21 papers in training set
Top 0.2%
2.7%
8
Frontiers in Genetics
197 papers in training set
Top 4%
2.1%
9
European Journal of Immunology
57 papers in training set
Top 0.2%
1.9%
10
The Journal of Immunology
146 papers in training set
Top 0.7%
1.9%
11
Annals of the Rheumatic Diseases
32 papers in training set
Top 0.4%
1.9%
12
Nature Communications
4913 papers in training set
Top 50%
1.8%
13
Journal of Experimental Medicine
106 papers in training set
Top 2%
1.5%
14
Immunology & Cell Biology
11 papers in training set
Top 0.1%
1.5%
15
International Journal of Molecular Sciences
453 papers in training set
Top 10%
1.3%
16
PLOS ONE
4510 papers in training set
Top 58%
1.3%
17
Journal of Allergy and Clinical Immunology
25 papers in training set
Top 0.5%
1.2%
18
Allergy
23 papers in training set
Top 0.4%
1.2%
19
Molecular Immunology
14 papers in training set
Top 0.3%
1.2%
20
European Respiratory Journal
54 papers in training set
Top 1%
1.2%
21
eLife
5422 papers in training set
Top 49%
1.2%
22
Clinical & Translational Immunology
22 papers in training set
Top 0.2%
0.8%
23
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 44%
0.7%
24
PLOS Pathogens
721 papers in training set
Top 9%
0.7%
25
ImmunoHorizons
21 papers in training set
Top 0.2%
0.7%
26
Human Molecular Genetics
130 papers in training set
Top 4%
0.7%
27
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 6%
0.7%
28
Communications Biology
886 papers in training set
Top 26%
0.7%
29
Frontiers in Physiology
93 papers in training set
Top 7%
0.6%
30
Blood
67 papers in training set
Top 2%
0.6%